Alhydrogel
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Alhydrogel, covering 2012-01-09 to 2024-07-10. Get the full timeline:
Most recent: Clinical Trial Update: GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age [Phase 2, Phase 3]